CD8A and neoplasm: In the current study, we observed that mice vaccinated with the E7 peptide-based vaccine combined with PADRE peptide and poly(I:C) generate the strongest E7-specific CD8+ T cell immune responses and therapeutic anti-tumor effects against TC-1 tumors among the different vaccination groups.